Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
48.8M
-
Shares change
-
+767K
-
Total reported value, excl. options
-
$3.75B
-
Value change
-
+$80.2M
-
Put/Call ratio
-
1.12
-
Number of buys
-
74
-
Number of sells
-
-81
-
Price
-
$76.87
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2018
185 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.8M shares
of 96M outstanding shares and own 50.86% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.09M shares), Capital Research Global Investors (5.76M shares), BlackRock Inc. (4.39M shares), VANGUARD GROUP INC (4.08M shares), Capital International Investors (3.6M shares), FMR LLC (3.46M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.8M shares), STATE STREET CORP (1.65M shares), FEDERATED INVESTORS INC /PA/ (1.42M shares), and AMERIPRISE FINANCIAL INC (1.33M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.